SG11201501958QA - Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease - Google Patents

Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease

Info

Publication number
SG11201501958QA
SG11201501958QA SG11201501958QA SG11201501958QA SG11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA
Authority
SG
Singapore
Prior art keywords
parkinson
diabetes
depression
disease
treatment
Prior art date
Application number
SG11201501958QA
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201501958QA publication Critical patent/SG11201501958QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
SG11201501958QA 2012-09-14 2013-09-11 Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease SG11201501958QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12184360 2012-09-14
PCT/EP2013/068769 WO2014041007A1 (en) 2012-09-14 2013-09-11 Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease

Publications (1)

Publication Number Publication Date
SG11201501958QA true SG11201501958QA (en) 2015-04-29

Family

ID=47044779

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501958QA SG11201501958QA (en) 2012-09-14 2013-09-11 Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease

Country Status (35)

Country Link
US (1) US9487501B2 (no)
EP (1) EP2895477B1 (no)
JP (2) JP2015531782A (no)
KR (1) KR101706486B1 (no)
CN (2) CN107903251A (no)
AR (1) AR092537A1 (no)
AU (1) AU2013314388B2 (no)
BR (1) BR112015004511B1 (no)
CA (1) CA2882821C (no)
CL (1) CL2015000580A1 (no)
CR (1) CR20150087A (no)
DK (1) DK2895477T3 (no)
EA (1) EA026062B1 (no)
ES (1) ES2654653T3 (no)
HK (2) HK1252981A1 (no)
HR (1) HRP20171981T1 (no)
HU (1) HUE037689T2 (no)
IL (1) IL237332B (no)
LT (1) LT2895477T (no)
MA (1) MA37944B2 (no)
MX (1) MX363362B (no)
MY (1) MY178667A (no)
NO (1) NO2895477T3 (no)
NZ (1) NZ705154A (no)
PE (1) PE20150735A1 (no)
PH (1) PH12015500489A1 (no)
PL (1) PL2895477T3 (no)
PT (1) PT2895477T (no)
RS (1) RS56747B1 (no)
SG (1) SG11201501958QA (no)
SI (1) SI2895477T1 (no)
TW (1) TWI610926B (no)
UA (1) UA113776C2 (no)
WO (1) WO2014041007A1 (no)
ZA (1) ZA201501126B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101800594B1 (ko) * 2014-07-30 2017-11-22 에프. 호프만-라 로슈 아게 미량 아민 결합 수용체(taar) 조절제로서 6-아미노-5,6,7,8-테트라하이드로나프탈렌-2-일 또는 3-아미노크로만-7-일 유도체
SG11201807516UA (en) 2016-03-17 2018-09-27 Hoffmann La Roche 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
WO2018112420A1 (en) * 2016-12-15 2018-06-21 The Regents Of The University Of California Compositions and methods for treating cancer
MA55594A (fr) 2019-04-09 2022-02-16 Hoffmann La Roche Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune
TW202317537A (zh) * 2021-06-18 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 一種malt 1抑制劑及其製備方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
CA2676944C (en) 2007-02-15 2016-01-19 F. Hoffmann-La Roche Ag 2-aminooxazolines as taar1 ligands
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2012063896A1 (ja) * 2010-11-11 2012-05-18 第一三共株式会社 新規ピラゾールアミド誘導体
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives

Also Published As

Publication number Publication date
MY178667A (en) 2020-10-20
NO2895477T3 (no) 2018-03-31
CA2882821A1 (en) 2014-03-20
MA37944B2 (fr) 2017-10-31
EP2895477A1 (en) 2015-07-22
PT2895477T (pt) 2017-12-29
JP2017122103A (ja) 2017-07-13
MX2015002900A (es) 2015-06-03
UA113776C2 (xx) 2017-03-10
EA201590454A1 (ru) 2015-09-30
HUE037689T2 (hu) 2018-09-28
KR20150054947A (ko) 2015-05-20
HK1252981A1 (zh) 2019-06-06
ES2654653T3 (es) 2018-02-14
CL2015000580A1 (es) 2015-07-10
US9487501B2 (en) 2016-11-08
BR112015004511A2 (pt) 2017-07-04
CN107903251A (zh) 2018-04-13
BR112015004511B1 (pt) 2022-08-02
PE20150735A1 (es) 2015-05-17
IL237332B (en) 2018-07-31
MX363362B (es) 2019-03-21
AU2013314388B2 (en) 2016-07-14
TWI610926B (zh) 2018-01-11
PL2895477T3 (pl) 2018-03-30
RS56747B1 (sr) 2018-03-30
KR101706486B1 (ko) 2017-02-13
JP2015531782A (ja) 2015-11-05
LT2895477T (lt) 2018-01-25
EP2895477B1 (en) 2017-11-01
WO2014041007A1 (en) 2014-03-20
ZA201501126B (en) 2016-01-27
DK2895477T3 (en) 2018-01-15
BR112015004511A8 (pt) 2021-11-03
AR092537A1 (es) 2015-04-22
JP6529998B2 (ja) 2019-06-12
SI2895477T1 (en) 2018-02-28
HRP20171981T1 (hr) 2018-02-09
AU2013314388A1 (en) 2015-03-05
PH12015500489B1 (en) 2015-04-20
TW201425308A (zh) 2014-07-01
EA026062B1 (ru) 2017-02-28
HK1206720A1 (en) 2016-01-15
CR20150087A (es) 2015-04-06
IL237332A0 (en) 2015-04-30
PH12015500489A1 (en) 2015-04-20
CA2882821C (en) 2018-05-22
US20150218131A1 (en) 2015-08-06
MA37944A1 (fr) 2016-04-29
CN104619700A (zh) 2015-05-13
NZ705154A (en) 2018-03-23

Similar Documents

Publication Publication Date Title
IL269511A (en) New therapeutic approaches to treat Parkinson's disease
EP2911664A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL237743A0 (en) A combination of rasagiline and pridofidine for the treatment of neurodegenerative diseases, and specifically for the treatment of Huntington's disease
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
HRP20181623T1 (hr) Modulatori x receptora jetre (lxr) za liječenje bolesti, poremećaja i stanja kože
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3-
CA2871774C (en) Use of n-acetylcysteine amide in the treatment of disease and injury
HK1252981A1 (zh) 作為用於治療數種疾病如抑鬱症、糖尿病和帕金森病的taar調節劑的吡唑甲酰胺衍生物
EP2968222A4 (en) METHOD, COMPOSITIONS AND DEVICES FOR TREATING MOTOR DISTURBANCES AND DEPRESSION SYMPTOMS RELATED TO MORBUS PARKINSON
UA112981C2 (uk) Варіант людського gdnf
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
TH1501001422A (th) อนุพันธ์ไพราโซลคาร์บอกซาไมด์ในฐานะ taar โมดูเลเตอร์สำหรับใช้ในการรักษา ความผิดปกติหลายชนิดอย่างเช่นภาวะซึมเศร้า, เบาหวาน และโรคพาร์กินสัน
IL241397A0 (en) Preparations and devices for treating the symptoms of Parkinson's disease
WO2013114403A8 (en) Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders
GB201104720D0 (en) Carncin - The use of L-carnosine and cinnamon in the treatment of alzheimer's disease